A Phase 1, Open-label, Sequential-group, Single-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 592 Administered Subcutaneously in Healthy Chinese, Japanese, and Caucasian Subjects

20200102

The primary objective of this study is to evaluate the pharmacokinetics (PK) of efavaleukin alfa after single subcutaneous (SC) administration in healthy Chinese, Japanese, and Caucasian participants.

2021-08-09

2022-10-03

2022-10-03

Completed

Early phase I

32

Inclusion Criteria: * Healthy male or female participants, between 18 and 55 years of age (inclusive) at the time of Screening. * Chinese, Japanese, or Caucasian participant: * Chinese participants must be of Chinese ancestry (4 grandparents and biological parents). * Japanese participants must be first- or second-generation Japanese (4 grandparents and biological parents; participant or both of their parents must have been born in Japan). * Caucasian participants are those who self-identify exclusively as such on the electronic case report form (eCRF) and also identify their biological parents as such. * In good health, determined by no clinically significant findings from medical history, physical examinations, 12-lead electrocardiogram (ECG), vital signs measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia \[eg, suspicion of Gilbert's syndrome based on total and direct bilirubin\] is not acceptable) as assessed by the Investigator (or designee). * Body mass index between 17 and 30 kg/m\^2 (inclusive) at the time of Screening. Exclusion Criteria: * Evidence of scars, tattoos, or other skin lesions that may interfere with the injection site or injection site assessments. * History or evidence of clinically significant arrhythmia at Screening, including any clinically significant findings on the ECG taken at Check-in. * A QT interval corrected for heart rate using Fridericia's method (QTcF) interval \> 450 msec in male participants or \> 470 msec in female participants or history/evidence of long QT syndrome, at Screening or Check-in. * PR interval \> 210 msec, at Screening or Check-in. * Second- or third-degree atrioventricular (AV) block , at Screening or Check-in. * Systolic blood pressure (BP) \> 140 mmHg or \< 90 mmHg, or diastolic BP \> 90 mmHg, or HR \> 100 bpm, at Screening or Check-in. * Estimated glomerular filtration rate less than 60 mL/min/1.73 m\^2 as calculated by the Modification of Diet in Renal Disease equation, at Screening. * HbA1C ≥ 7%, at Screening or Check-in. * Participants who have received live vaccines within 5 weeks prior to Screening, or plan to receive live vaccines within 105 days after administration of an investigational product. * Positive hepatitis B or hepatitis C panel (ie, positive hepatitis B surface antigen, hepatitis B core antibody or hepatitis C antibody) at Screening, or a medical history for hepatitis B or C; and/or positive human immunodeficiency virus test, at Screening. Participants whose results are compatible with prior vaccination may be included. Participants with a history of hepatitis B vaccination without a history of hepatitis B or C are allowed to participate. * Consumption of foods and beverages containing poppy seeds within 7 days prior to Check-in. * History of alcoholism or drug/chemical abuse within 1 year prior to Check-in. * Use of tobacco- or nicotine-containing products within 6 months prior to Check-in. * Positive test for illicit drugs, cotinine (tobacco or nicotine use), and/or alcohol use at Screening or Check-in. * Female participants with a positive pregnancy test at Screening or Check-in. * Participant has received a dose of an investigational drug within the past 90 days or 5 half-lives of the drug, whichever is longer, prior to Check-in. * Donation of blood from 90 days prior to Check-in, plasma from 2 weeks prior to Check-in, or platelets from 6 weeks prior to Check-in. * Participants with abnormal laboratory results for alanine aminotransferase (ALT) or aspartate aminotransferase (AST) (ie, \> upper limit of normal) and total bilirubin (ie, \> upper limit of normal) at Screening and Check-in.

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SEQUENTIAL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 32, 'type': 'ACTUAL'}}

2024-03-29